BOAN BIOTECH Announces Executive Reshuffle and Strategic Committee Changes

Stock News03-31

BOAN BIOTECH (06955) has announced that Dr. Dou Changlin, an executive director, has reached the statutory retirement age and has voluntarily resigned from his positions as executive director, head of research and development, chief operating officer, and chairman of the strategic committee. Following his resignation, effective March 31, 2026, Dr. Dou will no longer hold any position within the company, its subsidiaries, or associated companies. Effective from the same date, Ms. Jiang Hua, the chairperson of the board and an executive director, will assume the role of chairman of the strategic committee. Additionally, Mr. Wang Shenghan, an executive director, will be appointed as a member of the strategic committee.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment